menu

Optimizing the Use of Immunotherapy in the First-Line Maintenance Setting for Metastatic Urothelial Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Optimizing the Use of Immunotherapy in the First-Line Maintenance Setting for Metastatic Urothelial Carcinoma

3 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Petros Grivas, MD, PhD
    Professor, Medical Oncology
    University of Washington School of Medicine
    Professor, Clinical Research Division
    Fred Hutchinson Cancer Center
    Seattle, WA

    Consulting Fees: 4D Pharma, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, PureTech, QED Therapeutics, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen Pharma

    Research: Acrivon, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, QED Therapeutics

    Thomas Powles, MD, PhD
    Professor of Genitourinary Oncology
    Director, Barts Cancer Centre
    St. Bartholomew's Hospital
    London, England

    Consulting Fees: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elelixis, Incyte, Ipsen, Johnson & Johnson, MashupMD, Merck Serono, MSD, Novartis, Pfizer, Roche, Seagen

    Research: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson &Johnson, Merck Serono, MSD, Novartis, Pfizer, Roche, Seagen

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify key long-term clinical trial data on new maintenance regimens for metastatic urothelial carcinoma (mUC)
    • Assess the benefit of maintenance regimens for mUC in terms of overall survival, progression-free survival, and safety
    • Apply global guidelines to the identification of patients who may be eligible for maintenance treatment and the recommended sequencing of therapies for these subsets of patients
    • Formulate strategies for the optimal delivery of immunotherapy in the maintenance setting, with consideration as to its timing, duration, and safe administration
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, and the multidisciplinary care team.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until July 19, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/.05 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-23-033-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Petros Grivas, MD, PhD
    Professor, Medical Oncology
    University of Washington School of Medicine
    Professor, Clinical Research Division
    Fred Hutchinson Cancer Center
    Seattle, WA

    Consulting Fees: 4D Pharma, Aadi Bioscience, Asieris Pharmaceuticals, Astellas, AstraZeneca, BostonGene, Bristol Myers Squibb, CG Oncology, Dyania Health, Exelixis, Fresenius Kabi, Genentech, Gilead Sciences, Guardant Health, ImmunityBio, Infinity Pharmaceuticals, Janssen, Lucence, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, PureTech, QED Therapeutics, Regeneron, Roche, Seattle Genetics, Silverback Therapeutics, Strata Oncology, UroGen Pharma

    Research: Acrivon, Bavarian Nordic, Bristol Myers Squibb, Clovis Oncology, Debiopharm Group, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Merck KGaA, Mirati Therapeutics, MSD, Pfizer, QED Therapeutics

    Thomas Powles, MD, PhD
    Professor of Genitourinary Oncology
    Director, Barts Cancer Centre
    St. Bartholomew's Hospital
    London, England

    Consulting Fees: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Elelixis, Incyte, Ipsen, Johnson & Johnson, MashupMD, Merck Serono, MSD, Novartis, Pfizer, Roche, Seagen

    Research: Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson &Johnson, Merck Serono, MSD, Novartis, Pfizer, Roche, Seagen

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mara Siegel has nothing to disclose.
    • Rosanne Strauss has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify key long-term clinical trial data on new maintenance regimens for metastatic urothelial carcinoma (mUC)
    • Assess the benefit of maintenance regimens for mUC in terms of overall survival, progression-free survival, and safety
    • Apply global guidelines to the identification of patients who may be eligible for maintenance treatment and the recommended sequencing of therapies for these subsets of patients
    • Formulate strategies for the optimal delivery of immunotherapy in the maintenance setting, with consideration as to its timing, duration, and safe administration
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, urologists, and the multidisciplinary care team.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. Approval is valid until July 19, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .50 contact hours/.05 CEUs of pharmacy contact hours.1 

    The Universal Activity Number for this program is JA0006235-0000-23-033-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4.

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes.

    Provided in Partnership with: 

  • Commercial Support

    This activity is supported by an independent educational grant from the healthcare business of Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule16 Jul 2024